Financial PerformanceTransMedics reported Q3 revenue of $108.8M, missing the $118.6M estimate and consensus of $115.0M.
Growth Concerns2025 consensus estimates are likely too high and expect further downward revisions.
Market CompetitionTMDX is facing intensifying competition from a variety of directions including OrganOx, Paragonix Technologies, and normothermic regional perfusion.